tead inhibitor sw-682
Generic: TEAD Inhibitor SW-682
tead inhibitor sw-682: developed by 1 company · 1 clinical trial tracked.
tead inhibitor sw-682 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect tead inhibitor sw-682 to SWTX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could tead inhibitor sw-682 → SWTX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Advanced Solid TumorMesothelioma, Malignant
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| SpringWorks Therapeutics, Inc. (SWTX) Advanced Solid Tumor | Phase 1 |
Clinical Trials (1)
A Phase 1a/1b Dose Escalation, Dose Expansion Study of SW-682 in Participants With Advanced Solid Tumors Enriched for Those With Hippo Pathway Mutations
Primary endpoint: Incidence of Adverse Events (Part 1 Only)
Interventionalopen186 targetStarted 2024-07Completion 2027-018 sites · United StatesSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Frequently asked questions
Who is developing tead inhibitor sw-682?
tead inhibitor sw-682 is being developed by SpringWorks Therapeutics, Inc..
How many clinical trials involve tead inhibitor sw-682?
BioSniper tracks 1 clinical trial involving tead inhibitor sw-682.